ArticleEClinicalMedicine2024

Cabozantinib plus atezolizumab in previously untreated advanced hepatocellular carcinoma and previously treated gastric cancer and gastroesophageal junction adenocarcinoma: results from two expansion cohorts of a multicentre, open-label, phase 1b trial (COSMIC-021).

Daneng Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.